How do constitutively active signaling pathways impact response to treatment in pediatric T-ALL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Andrea Biondi, University of Milano-Bicocca, Milan, IT. We asked, How do constitutively active signaling pathways impact response to treatment in pediatric T-cell ALL (T-ALL)?

Pediatric T-ALL accounts for 15% of total pediatric ALL cases. During the last 10 years, studies have focused on the deep analysis of genomic heterogeneities of T-ALL. In this podcast, Biondi discusses assessing molecular response as a predictive parameter for identifying the subgroup of patients with T-ALL with a dismal prognosis, and the constitutively active signaling pathways in pediatric T-ALL.